Collectively, our data suggest that dual blockade of ER and PRMT5 can effectively suppress tumor growth of ER+/RB-deficient breast cancer, thus providing the basis for testing this therapeutic combination in patients with this refractory breast cancer genotype. This evidence concerns the gene PRMT5 and breast carcinoma.